The FDA on Monday approved an experimental drug that aims to slow the progression of Alzheimer's disease, despite the fact that a key FDA panel late last year said that questions remain about its ...
The pursuit of a cure for Alzheimer's disease is becoming an increasingly competitive and contentious quest, with recent ...
With Biogen gaining FDA approval for its Alzheimer’s drug, aducanumab, questions have started to swirl around how health insurers will cover the $56,000-a-year treatment. 1. The FDA approved Biogen’s ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback